Alzheimer's disease (AD) is characterized by extracellular amyloid-b (Ab) deposition, which activates microglia, induces neuroinflammation and drives neurodegeneration. Recent evidence indicates that soluble pre-fibrillar Ab species, rather than insoluble fibrils, are the most toxic forms of Ab. Preventing soluble Ab formation represents, therefore, a major goal in AD. We investigated whether microvesicles (MVs) released extracellularly by reactive microglia may contribute to AD degeneration. We found that production of myeloid MVs, likely of microglial origin, is strikingly high in AD patients and in subjects with mild cognitive impairment and that AD MVs are toxic for cultured neurons. The mechanism responsible for MV neurotoxicity was defined in vitro using MVs produced by primary microglia. We demonstrated that neurotoxicity of MVs results from (i) the capability of MV lipids to promote formation of soluble Ab species from extracellular insoluble aggregates and (ii) from the presence of neurotoxic Ab forms trafficked to MVs after Ab internalization into microglia. MV neurotoxicity was neutralized by the Ab-interacting protein PrP and anti-Ab antibodies, which prevented binding to neurons of neurotoxic soluble Ab species. This study identifies microglia-derived MVs as a novel mechanism by which microglia participate in AD degeneration, and suggest new therapeutic strategies for the treatment of the disease. Cell Death and Differentiation (2014) 21, 582-593; doi:10.1038/cdd.2013.180; published online 13 December 2013
Alzheimer's disease (AD) is the major cause of dementia in humans. Neuronal loss and cognitive decline occurring in AD patients are traditionally linked to the accumulation in the brain of extracellular plaques consisting of short amyloid-b (Ab) peptides of 39-42 amino acids, generated by amyloidogenic cleavage of the amyloid precursor protein. 1 Among Ab peptides, Ab 1-42 and pyroglutamate-modified Ab very rapidly aggregate and initiate the complex multistep process that leads to mature fibrils and plaque. 2, 3 Although association of amyloid plaques with AD has long been assumed, Ab load does not correlate with neuronal loss 4, 5 and high plaque burden does not necessarily lead to dementia in humans. 6, 7 Accordingly, recent evidence clearly showed that the amyloid load reaches a plateau early after the onset of clinical symptoms in AD patients 8 and does not substantially increase in size during clinical progression. 9 These observations agree with the current view that small, soluble pre-fibrillar Ab species, rather than plaques formed by insoluble Ab fibrils, are the most toxic forms of Ab. 10 These cause synaptic dysfunction and spine loss, and correlate most closely with the severity of human AD. 5, 8, 11 Recent biochemical studies indicated that natural sphingolipids and gangliosides, whose metabolism has been shown to be altered in AD patients, 12 destabilize and rapidly resolubilize long Ab fibrils to neurotoxic species. 13 These studies also showed that phospholipids stabilize toxic oligomers from monomeric peptides. 14 The toxicity of small soluble Ab species has been proposed to depend on the interaction with specific neuronal proteins, such as the NMDA receptor 15 or the prion protein (PrP C ), 16 which modulates NMDA receptors through Fyn kinase. 17 Alternatively, soluble Ab oligomers may damage neurons by binding to multiple membrane components, including lipids, thereby changing membrane permeability and causing calcium ion leakage into the cell. 5, 18 Neuroinflammation arguably has a role in promoting neurotoxicity of Ab plaques. This is suggested by several lines of evidence: (i) subjects with high plaque burden without dementia show virtually no evidence of neuroinflammation; between the cognitive status and activation of microglia, the immune cells of the nervous system, in AD patients; (iii) activation of microglia increases linearly throughout the disease course and correlates with AD neurodegeneration. 8 Moreover, recent studies demonstrating that variants of TREM2 and CD33, two receptors expressed in microglial cells, increase the risk for late-onset AD 21, 22 have refocused the spotlight on microglia as a major contributing factor in AD. Although multiple preclinical evidence indicates that microglia activation promotes neuronal dysfunction and neuron elimination 23, 24 and accelerates AD progression, 19, 25, 26 the molecular mechanisms by which microglia exert neurotoxicity remain largely unknown.
We have recently described a novel mechanism of cell-tocell communication in the brain, by which reactive microglia propagate an inflammatory signal through the release of extracellular membrane microvesicles (EMVs), which bud from the cell surface, called shed microvesicles (MVs) or ectosomes. MVs are shed by microglia upon ATP activation 27 and originate from lipid rafts, 28 where the ATP receptor P2X 7 is localized. 29 Shed MVs selectively accumulate various cellular components, including soluble and integral proteins, lipids and nucleic acids and their composition reflects the activation state of donor microglia. Notably, microglia-derived MVs in the cerebrospinal fluid (CSF) have been recently identified as a novel biomarker of brain inflammation in humans. 30, 31 The observation that typical proteins of EMVs, like flotilin, accumulate in the plaques of AD brain, 32 together with evidence that activated microglia constantly surround amyloid deposits, 33 prompted us to investigate whether EMVs may be involved in the spatiotemporal propagation of Ab pathology through the brain. Here we show that production of MVs is extremely high in patients with AD and that microglial MVs, either shed in vitro or isolated from the CSF of AD patients, promote generation of soluble neurotoxic Ab species, thereby acting as potent drivers of neuronal damage.
Results
The combination of Ab 1-42 and microglia-derived MVs is neurotoxic in vitro. The evidence that natural lipids may shift the equilibrium between insoluble and soluble Ab toward highly toxic soluble species 13, 34 prompted us to test whether MVs shed from microglial cells may promote Ab neurotoxicity. Ab 1-42 (4 mM) dissolved in dimethyl sulfoxide (DMSO) was incubated overnight with MVs derived from rat primary microglia (1 mg/100 ml) at 37 1C in neuronal medium and subsequently exposed to cultured hippocampal neurons for 1 h. Overnight pre-incubation of Ab 1-42 with MVs yielded a neurotoxic mixture that significantly increased the percentage of dead neurons, as assessed 24 h later by propidium iodide (PI) and calcein staining (Figures 1a and b; number of experiments ¼ 4). Notably, neither MVs alone nor MVs incubated overnight with scrambled Ab 1-42 significantly affected neuronal survival (Figure 1b) . Ab 1-42 alone, dissolved in DMSO and incubated overnight at 37 1C in neuronal medium in the absence of MVs, from now on called aggregated Ab 1-42 barely affected neuronal viability, even when supplemented with MVs just before neuron challenge (acutely added MVs, AA-MVs- Figure 1b) . Collectively, these findings indicate that overnight pre-incubation of aggregated Ab 1-42 with MVs is required for the development of neurotoxicity. Ab 1-42 pre-incubated with MVs induced cell death very rapidly. One hour after exposure to Ab 1-42 preincubated with MVs, about 15-30% of neurons loaded with the calcium dye Fura-2 displayed an abnormally high level of cytosolic calcium (Figures 1b and c ; n ¼ 10) and were positive for the early apoptotic marker annexin-V (Figure 1e ; n ¼ 6). MVs alone, pre-incubated overnight in neuronal medium, also induced a slight increase in intracellular calcium concentrations (Figure 1d ). Immunofluorescence analysis with the neuronal marker b-3 tubulin and the pre-and post-synaptic markers V-Glut-1 and PSD-95 revealed that processes of neurons treated with combined Ab 1-42 and MVs were fragmented and showed reduced synaptic density (Figures 1f and g ). Dendrite damage was associated to a marked decrease of MAP-2 immunoreactivity (Figure 3f ). The toxic effect of Ab 1-42 in combination with MVs was largely prevented when neurons were exposed to the mixture in the presence of the glutamate receptors antagonists APV (100 mM) and CNQX (20 mM), as evaluated by quantification of cytoplasmic calcium (n ¼ 4), annexin-V (n ¼ 2) or PI/calcein (n ¼ 2) staining (Figures 1h-j) . This suggests excitotoxic damage as the cause of neuronal death.
Shed MVs promote formation of soluble forms of Ab 1-42. Ab 1-42 pre-incubated overnight with MVs was partitioned into two phases by centrifugation for 30 min at 10 000 Â g. The neurotoxicity of the two fractions was analyzed by monitoring cytosolic calcium in cultured neurons. Whereas the supernatant retained a high degree of toxicity, the pellet was largely inert (Figure 2a left; n ¼ 3). Similar results were obtained by quantification of dead neurons by PI/calcein assay (Figure 2a right; n ¼ 3). This suggested that soluble molecules, not associated to MVs, either generated from Ab 1-42 synthetic peptides or deriving from MVs were mainly responsible for toxicity.
The inflammatory mediators IL-1b and TNFa are among the molecules contained in microglial MVs that, through potentiation of NMDA channel activity, may induce excitoxicity. 27, 35 As IL-1b and TNFa expression is upregulated in M1 proinflammatory microglia, and downregulated in M2 anti-inflammatory cells, we analyzed neuron viability after exposure to Ab 1-42 incubated with MVs produced by either LPS-primed M1 microglia or M2 cells, polarized with IL-4. Similar alterations of cytoplasmic calcium were observed in neurons exposed to Ab 1-42 in combination with MVs derived from M1 or M2 microglia (Figure 2b ; n ¼ 3) or exposed to the neurotoxic mixture in the presence of IL-1b-and TNFa-neutralizing antibodies (Figure 2c ; n ¼ 4). These data rule out the possibility that excitotoxicity of Ab 1-42 in combination with MVs depends on cytokine leakage from MVs.
We then investigated whether neurotoxicity of Ab 1-42/ MVs mixture could be due to the presence of neurotoxic soluble Ab forms. Negative staining electron microscopic analysis revealed the presence of both globular structures of diameter between 4 and 8 and 5-8 nm wide Ab fibrils in samples of aggregated Ab 1-42 incubated overnight with MVs. After fractionation into two phases by centrifugation, Binding of newly generated soluble Ab 1-42-488 to neurons is competed by PrP c . We next attempted to visualize soluble Ab 1-42 forms, generated in the presence of MVs, by imaging their binding to cultured neurons. We observed that culture exposure to 488-Ab 1-42/MVs mixture for 1 h produced a strong labeling of MAP-2-positive dendrites, which exceeded by almost fourfolds the staining produced by fluorescent Ab 1-42 alone (Figures 3a and b) . 488-Ab 1-42 binding to dendrites was paralleled by a marked reduction of MAP-2 staining (Figure 3a) , according to previous evidence. 36 No preferential association of 488-Ab1-42 with synapses was detected (data not shown). Fractionation of 488-Ab 1-42/MVs mixture into two phases by centrifugation showed that the fluorescent Ab1-42 forms capable of binding to neurons were mainly recovered in the soluble fraction (Supplementary Figures S1C-E) . Notably, Ab binding was specifically competed by the high-affinity oligomer-interacting protein PrP Finally, as the soluble but not the fibrillar Ab forms activate NMDA receptors, 37 we used a bioassay to assess the capability of Ab species generated in the presence of MVs to enhance NMDA receptor activity. FURA-2-loaded neurons, expressing functional NMDA receptors, were used as sensor cells for soluble Ab 1-42. By this approach, we detected calcium responses in about 30% of neurons exposed to Ab 1-42 in combination with MVs, but not Ab 1-42 or shed MVs alone (Figure 3e ; n ¼ 3). No calcium transients were observed upon neuron challenging with scrambled Ab 1-42 and MVs (data not shown). Calcium responses evoked by Ab 1-42 pretreated with MVs were inhibited by the NMDA receptor antagonist APV (100 mM) (Figures 3f and g; n ¼ 3) . Direct HPLC measurements of glutamate content in MVs or Ab 1-42/MVs preparations revealed concentrations lower than 1 mM, that is, the minimal concentration required to detect calcium influx in our system (mean glutamate concentration: 137 ± 70 nM, MVs alone; 196 ± 115 nM, Ab 1-42/MVs mixtures). These data exclude possible interference of ambient glutamate in the NMDA-dependent calcium response. Therefore, soluble Ab 1-42 species generated in the presence of shed MVs are able to activate NMDA calcium channels, triggering excitotoxicity.
MVs carry neurotoxic species generated from internalized Ab 1-42. As amyloid plaques are surrounded by activated microglia that actively phagocyte and degrade Ab, we investigated whether MVs may contain toxic Ab species, generated from internalized peptides. Confocal analysis of microglia exposed to Ab1-42 for 24-48 h, extensively washed and stained with 6E10 anti-Ab antibody, revealed intracellular Ab aggregates, which can reach the plasma membrane, stained by IB4 (Figure 4a) . Notably, few Ab and IB4 double-positive particles were detected extracellularly in cell proximity (Figure 4a , bottom right panel), suggesting that EMVs derived from Ab-loaded microglia may indeed contain Ab species. We explored this hypothesis by western blot analysis of EMVs collected from supernatant of microglia exposed to biotynilated Ab1-42. Upon ATP stimulation for 30 min, a condition that mimics an inflammatory context and favors shedding of MVs (P2 and P3 fraction) versus exosome (P4 fraction) release, 38 biotin-conjugated Ab1-42 was recovered in shed MVs, labeled by Tsg101 (Figure 4b , bottom panel). Consistently, SELDI-TOF mass spectrometry using 6E10 and 4G8 anti-Ab antibodies revealed the presence of preloaded Ab1-42 and of its cleavage product Ab1-40, along with traces of other carboxy-terminally truncated isoforms, in MVs shed from the plasma membrane (P2 þ P3 fractions) (Figure 4c ). Ten times less Ab was recovered in exosomes (P4 fraction) (Figure 4c ), although Ab1-42 species were clearly detectable in exosomes constitutively accumulated for 24 h in microglia supernatant (Supplementary Figure S3) . In line with the presence of Ab species, MVs derived from microglia stimulated for 48 h with 4 mM Ab 1-42 (Ab-MVs) were highly neurotoxic as compared with MVs derived from resting cells (Figure 4d , n ¼ 4). MV neurotoxicity was significantly decreased by anti-Ab antibodies. These data indicate that microglia internalize and generate Ab neurotoxic species, which are delivered to neurons in association with MVs, possibly on MV external membrane.
MVs from AD patients are neurotoxic. Recent results from our laboratories indicated that microglia-derived MVs are detectable in the CSF of humans and that their amount reflects the extent of microglia activation in the course of neuroinflammation. 30 To verify whether production of MVs from microglia could be elevated in AD, we collected CSF from patients with mild cognitive impairment (MCI) or AD, as well as from age-and gender-matched healthy donors. Flow cytometry analysis showed strikingly higher levels of MVs positive for the myeloid marker IB4 (more than 10-fold) in MCI and AD patients than in control subjects (Figure 5a ). IB4-positive MVs accounted for B65% of total EMVs detectable by flow cytometry. The number of IB4-positive MVs is correlated with a known CSF marker of neurodegeneration, namely, total Tau protein (Figure 5b ; Po0.0001). 39 We next examined the effects of MVs collected from AD patients on the equilibrium between soluble and insoluble Ab 1-42 species and assessed their toxic potential on cultured neurons. Confocal analysis of neurons exposed to 488-Ab 1-42 pre-incubated overnight with AD MVs revealed a threefold decrease in the content of fluorescent Ab aggregates (Figures 5c and d) and a parallel increase in fluorescent Ab species bound to dendrites ( Figures  5c and e) .
Consistently, with in vitro results showing that microglial MVs carry neurotoxic species generated from internalized Ab 1-42, MVs recovered from AD patients were highly toxic, as indicated by quantification of calcein À /PI þ dead neurons, as compared with MVs isolated from patients with multiple sclerosis (Figures  5f and g, n ¼ 3) . Neurotoxicity of AD MVs was significantly decreased by pretreatment with anti-Ab antibodies (Figure 5h ). Figure S4) .
Discussion
In the present study, we unveil a novel mechanism by which microglia contribute to neuronal damage in AD. We show that MVs, extracellularly released by cultured microglia, strongly increase Ab neurotoxicity in vitro. This effect is due to the lipid components of MVs, which promote formation of small soluble neurotoxic species from Ab 1-42 extracellular aggregates. Although Ab species can associate with MVs, as suggested by increased Ab flotation on sucrose gradient upon acute addition of MVs, most of neurotoxic soluble forms do not bind to MVs strongly. This is indicated by our observations that free Table S1 soluble Ab 1-42 species, not associated with MVs, bind efficiently to a subpopulation of neurons in vitro, increase NMDA receptor permeability and cause an excitotoxic damage. Conversely, Ab 1-42 forms pelleted along with MVs from Ab/MVs mixture display low toxicity and little neuronal-binding capacity. These data identify microglial MVs as an endogenous source of lipids able to shift the equilibrium toward toxic Ab species. This conclusion is in complete agreement with previous evidence that brain membrane lipids, including phosho-and (glycol)sphingolipids, favor formation of soluble forms, either promoting solubilization of inert fibrils, 13 or hindering their conversion to insoluble fibrils.
14 Interestingly, exosomes released by neurons have been found to promote rather than reduce Ab fibrillogenesis, 40 thus indicating that lipid composition of different EMVs generated by distinct cell types may have opposite effects on Ab extracellular assembly. Notably, MVs have a distinct repertoire of lipids not only compared with exosomes (our unpublished data) 41 but also to the plasma membrane of origin. Indeed, MVs are enriched in cholesterol, sphingomyelin and ceramide, and contain lipid raft elements, 28 including GM1 and GM3 gangliosides and flotillin-2. 42 Accordingly, artificial liposomes, composed of the main phospholipids of the plasma membrane, neither induce fibril solubilization nor promote Ab neurotoxicity. Lipidomic profiling of microglial MVs will identify endogenous lipids responsible for the generation of neurotoxic Ab species, which could themselves represent putative AD biomarkers. 9, 43, 44 MV-mediated Ab processing, leading to neurotoxic forms does not occur only extracellularly. Indeed, microglial MVs also contain toxic forms generated from internalized Ab 1-42. It has been previously shown that a fraction of intracellular Ab can be released through exosomes by neurons and oligodendrocytes. 32, [45] [46] [47] In addition, phagocytosed Ab has been found to be re-secreted from microglia, although through an undefined mechanism. 48 We now show that microglia release neurotoxic Ab 1-42 and Ab 1-40 species in association with MVs. This is the first evidence that microglia -which control extracellular plaque load 49, 50 by phagocytosis and degradation of Ab fibrils or macropinocytosis of soluble Ab 51, 52 -may seed and feed formation of neurotoxic amyloids throughout the brain. MV-mediated release of neurotoxic Ab forms likely occurs when intracellular pathways of Ab degradation are saturated and production of MVs becomes a way for microglia to eliminate undigested Ab. Neurotoxic Ab species may be processed in early to late endosomes and lysosomes 53 after disassembly of phagocytosed Ab and sorted to the external surface of MVs through association with the GPI-anchored protein PrP C or GM1 gangliosides, all of which are localized to raft domains 42 and bind tightly Ab oligomers. 54 Alternatively, neurotoxic Ab species may be generated at the cell surface, 55 where components of the g-secretase complex, which can cleave the carboxyl terminal of Ab 1-42 at position 40 are also localized, 53 possibly inside lipid rafts. This sorting mechanism may be consistent with the proposed role of lipid rafts in setting up platforms to concentrate into MVs proteins destined to secretion. 28, 56 Finally, processing of Ab 1-42 to Ab 1-40 may even proceed within MVs. Indeed, previous evidence showed that neuron-derived EMVs contain some components of the gsecretase complex, 57 whereas the insulin-degrading enzyme, which proteolyzes Ab 1-42 and Ab 1-40, has been detected among cargo proteins of microglial EMVs. 58 The significant decrease in neurotoxicity observed upon pretreatment with anti-Ab antibodies strongly supports the theory that neurotoxic Ab forms are in fact localized to the outer lipid bilayer of MVs. However, further studies are required to unequivocally define the topology of Ab species and to clarify whether Ab forms are actually associated to the extracellular membrane of shed MVs.
Our findings have clear clinical implications. First, production of MVs is very high in MCI and AD patients, reflecting microgliosis, 30 which typically characterizes the disease. 8 Second, MVs collected from the CSF of AD patients promote extracellular formation of neurotoxic Ab species similar to MVs shed from cultured cells. Finally, MVs collected from AD patients are extremely toxic for cultured neurons and their neurotoxicity results, at least in part, from their Ab cargo. However, it is still to be defined whether MVs may associate with toxic forms of Ab present in the parenchyma/blood vessel as well as plaques during their travel to CSF. In agreement with their pathogenic role, levels of microglia-derived MVs are positively correlated with classical biomarkers of neuronal injury such as tau 39 in MCI and AD subjects, and with damage to white matter structures of the temporal lobe in MCI patients, as revealed by MRI scans (Dalla Libera et al., manuscript in preparation). Correlation between microglia-derived MVs and brain damage suggests that MVs may represent a novel companion tool for AD diagnosis, and paves the way for future therapies targeting MVs to control the impact of neurotoxic Ab species on brain function. We anticipate that analysis of Ab content and lipidomic profiling of MVs in a large cohort of AD and healthy subjects will clarify whether changes in the conformation and/or in the amount of Ab forms account for MV neurotoxicity. Furthermore, lipidomic profiling of human MVs will lead to the identification of new putative AD biomarkers, thereby increasing the diagnostic potential of MVs in AD.
Materials and Methods
Glial cells and MVs isolation. Primary rat microglial cells were isolated from mixed cultures of cortical and hippocampal astrocytes, established from E21 rat embryos and maintained as described previously. 27 All efforts were made to minimize animal suffering and to reduce the number of animals used in accordance with the European Communities Council Directive of September 20, 2010 (2010/63/UE). All procedures involving animals were performed according to the guidelines of the Institutional Animal Care and Use Committee of the University of Milan.
To induce MV shedding, microglia were exposed to ATP (1 mM) for 30 min in Krebs-Ringer solution (KRH). Shed MVs were pelletted from the supernatant at 10 000 Â g for 30 min, whereas exosomes were pelleted at 100 000 Â g for 1 h, as described previously. 38 For biochemical fractionation of shed MVs, total lipids were extracted through the method previously described 59 with 2 : 1 (by volume) of chloroform and methanol. The lipid fraction was evaporated under a nitrogen stream, dried and resuspended in PBS at 40 1C in order to obtain multilamellar vesicles. Small unilamellar vesicles were obtained by sonicating multilamellar vesicles.
Ab 1-42 preparations. Unless otherwise stated, Ab 1-42 (Anaspec, Fremont, CA, USA) was dissolved at a concentration of 2 mM in DMSO. The stock was kept at À 80 1C, directly diluted to 4 mM in neuronal medium and kept overnight at 37 1C. We refer to this Ab 1-42 preparation as aggregated Ab 1-42, to distinguish it from fibrillar Ab 1-42 preparation, which is detailed below. To prepare soluble and fibrillar Ab 1-42, the peptide was initially monomerized by dissolving it in 100% hexafluoroisopropanol (Sigma, St. Louis, MO, USA) to obtain a 1-mM solution and then aliquoted in sterile microcentrifuge tubes.
The hexafluoroisopropanol was removed under vacuum using a SpeedVac and the peptide film was stored (desiccated) at À 80 1C. Soluble Ab 1-42 was prepared as described by Klein et al. 60 Briefly, the peptide film was freshly resuspended in 100% DMSO to 5 mM, further diluted to 100 mM in F-12 medium (Invitrogen, Paisley PA4 9RF, UK) and incubated for 24 h at 5 1C. Following incubation it was centrifuged at 14 000 Â g for 10 min at 4 1C and the soluble forms were collected in the supernatant. For fibrillar Ab 1-42 preparation, Ab 1-42 or Hylite-488-Ab 1-42 peptide film freshly resuspended in DMSO was further diluted to 100 mM in 10 mM HCl. 61 It was vortexed for 15 s and incubated for 24 h at 37 1C. After incubation, it was diluted to 4 mM in neuronal medium.
The aggregation state of Ab 1-42 preparation was assessed by transmission electron microscopy with a Tecnai G2 T20 Twin microscope (FEI, Eindhoven The Netherlands).
ThT assay. Ab preparations, incubated or not with MVs, were diluted to 4 mM in KRH and incubated overnight at 37 1C. For ThT assays, ThT (Fisher Scientific, Waltham, MA, USA) was added to the Ab preparations and monitored in a PerkinElmer LS50 spectrofluorometer (Perkin-Elmer, Waltham, MA, USA). ThT fluorescence emission spectra were recorded between 465 and 565 nm with 5 nm slits, using an excitation wavelength of 450 nm. For the time course experiments, the samples were kept at 37 1C and aliquots of 100 ml were removed from the sample at each time point. The aliquots were mixed with ThT to obtain a final concentration of 10 mM and then their fluorescence spectra were acquired.
Neuronal cultures and in vitro stimulation. Primary cultures of hippocampal neurons were established from E18 rat pups as previously described, 62 plated onto poly-L-lysine-treated coverslips at 500 cells/mm 2 cell density and maintained in Neurobasal with 2% B27 supplement and 2 mM glutamine (neuronal medium). DIV hippocampal neurons (9-14) were exposed to Ab 1-42 (4 mM), to MVs (1 mg/100 ml) or to a combination of Ab 1-42 and MVs for 1 h. Ab 1-42, MVs or their combination were kept overnight at 37 C1 before being exposed to neurons. Neurons (1.7 Â 10 5 ) were exposed to MVs produced by 1 Â 10 6 microglia (microglia : neuron ratio, 6 : 1). In a set of experiments, Ab 1-42/MVs mixtures were added with anti-TNF-a plus anti-IL-1b antibodies (R&D, Minneapolis, MN, USA) or with the anti-Ab antibodies 6E10 (Covance, Emerville, CA, USA) plus A11 (Invitrogen, Life Technologies Ltd., Paisley, UK), or with the PrP C (4 mM) for 30 min before being exposed to cultured neurons. Immunocytochemical staining. Immunofluorescence staining of fixed neurons was performed using the following antibodies: rabbit anti-beta tubulin (Sigma) guinea pig anti-vGLUT-1 (Synaptic System, Gottingen, Germany), mouse anti-PSD-95 (UC Davis/NIH NeuroMab Facility, Davis, CA, USA) and mouse anti-MAP-2 (Synaptic System). Secondary antibodies were conjugated with Alexa-488, Alexa-555 or Alexa-633 fluorophores (Invitrogen, Life Technologies Ltd.). For quantification of V-glut-1 puncta per length unit, the length of single neuritis was measured using Image J 1.46r software, and the number of positive puncta whose dimension was greater than 0.01 mm was quantified.
Cell viability assays
Binding to neurons of Hylite-488-labeled Ab 1-42 (Anaspec) was quantified using Image J 1.46r software. Hylite-488-Ab 1-42 and b tubulin double-positive puncta were revealed by generating a Hylite-488-Ab 1-42/b tubulin double-positive image using the 'and' option of 'image calculator' function. A fixed threshold was then set in the double-positive image and, having selected the pixel area parameter at 3-infinite, total colocalizing area was quantified using the 'analyze particle' function. Total b tubulin fluorescence area was directly measured in b tubulin fluorescence images, after setting a fixed threshold using the 'analyze particle' function, as described above. Finally, total Hylite-488-Ab 1-42/b tubulincolocalizing area was normalized to total b tubulin area in each field. b tubulin was revealed by Alexa-633 fluorophore to avoid significant interference of Hylite-488 in the red channel. Quantification of binding was normalized to b tubulin towing to the decrease in MAP-2 immunofluorescence staining upon Ab 1-42 binding.
Maximum projection of confocal stacks in the x-y plane and z axis scans were generated using Image J 1.46r software.
Confocal imaging and measurements of fluorescent fibrils.
Hylite-488-Ab 1-42 fibrils (Anaspec) were prepared as described above, overnight exposed or not to MVs and incubated for 1 h with primary cultures of hippocampal neurons. Neurons were then fixed and stained for MAP-2. Fluorescence images of Ab 1-42 fibrils were acquired with a Leica SPE confocal microscope by an operator blinded to the study and analyzed using Image J 1.46r software. A fixed threshold was set on Hylite-488-Ab 1-42-positive images. After selecting the area parameter (mm) at 0.1-infinite, the area of single fibrils was automatically measured using the 'analyze particle' function. The percentage of fibrils with increasing area values -at intervals of 5 mm 2 -was calculated and the cumulative distribution plot was constructed using OriginPro 8 software (Microcal INC., Claymont, DE, USA).
Western blotting. Lysates of shed MVs and exosomes were separated by electrophoresis, blotted on nitrocellulose membrane and revealed using streptavidin (1 : 1500, Sigma), rabbit anti-alix (1 : 1000, Covalab, Billerica, MA, USA) and mouse anti-Tsg101 (1 : 1000, Abcam, Cambridge, UK). Immunoreactive bands were detected using SuperSignal West Femto Pierce ECL (Thermo Fisher Scientific Inc., Rockford, IL, USA) and ECL film (Amersham, GE Healthcare Limited, Upsala, Sweden).
Endogenous glutamate determination. Endogenous glutamate content was measured by high-performance liquid chromatography analysis following precolumn derivatization with o-phthalaldehyde and discontinuous triphase gradient separation on a C18 reverse-phase chromatographic column (10 Â 4.6 mm 2 , 3 mm; at 30 1C; Chrompack, Middleburg, The Netherlands) coupled with fluorometric detection (excitation wavelength 350 nm; emission wavelength 450 nm). Homoserine was used as an internal standard. 63 SELDI-TOF mass spectrometry. The immune-proteomic assay for Ab isoforms detection was performed as previously reported. 64 Briefly, 3 ml of the specific monoclonal antibodies (6E10 þ 4G8) (Covance) at total mAbs concentration of 0.125 mg/ml (concentration of each mAb 0.0625 mg/ml) were incubated in a humidity chamber for 2 h at RT to allow covalent binding to the PS20 ProteinChip Array (Bio-Rad, Hercules, CA, USA). Unreacted sites were blocked with Tris-HCl 0.5 M, pH 8 in a humid chamber at RT for 30 min. Each spot was first washed three times with PBS containing 0.5% (v/v) TritonX-100 and then twice with PBS. The spots were coated with 5 ml of sample and incubated in a humid chamber overnight. Each spot was first washed three times with PBS containing 0.1% (v/v) TritonX-100, twice with PBS and finally with deionized water. One microliter of a-cyano-4-hydroxy cinnamic acid (Bio-Rad) was added to coated spots. Mass identification was made using the ProteinChip SELDI System, Enterprise Edition (Bio-Rad).
ELISA quantification. Quantitative determination of Ab 1-42 was performed using innotest ELISA kit (Innogenetics, Gent, Belgium) according to the manufacturer's procedures. Absorbance was detected by 1420 Multilabel Counter Victor 2 (Perkin-Elmer).
Human subjects. Human CSF samples were obtained for diagnostic purposes from subjects with MCI (n ¼ 53), definitive AD (n ¼ 89) according to the Dubois criteria and from age-and sex-matched (Supplementary Table S1 ) cognitively preserved and neurologically healthy subjects, undergoing spinal anesthesia for orthopedic surgery, serving as controls (n ¼ 20). Clinical features of AD and MCI patients are described in Supplementary Table S1 . This research project was approved by the ethical committee of the San Raffaele Scientific Institute, and all subjects signed written informed consent.
Quantification and isolation of MVs from human CSF. Samples of CSF collected by lumbar puncture (200-300 ml) were analyzed by flow cytometry, as described previously. 30 Briefly, human CSF was stained with the myeloid marker IB4-FITC (Sigma). Labeled MVs were quantified within a fixed time interval on a Canto II HTS flow cytometer and analyzed using FCS 3 software. Using sidescatter and forward side-scatter, a vesicle gate was determined over the instrument noise (set by running PBS filtered through a 100-nm filter). Within this gate, IB4-positive events (number of events per ml) were evaluated as a parameter of MV concentration. In a set of experiments, after flow cytometry quantification, human MVs were pelletted at 10 000 Â g from the volume of CSF yielding 400 MVs, which is the amount produced in vitro by 1 Â 10 6 microglia. MVs were then resuspended in neuronal medium and exposed to 1.7 Â 10 5 neurons. Alternatively, MVs (10 000 Â g pellet) were processed and analyzed using SELDI-TOF mass spectrometry.
Statistical analysis. All data are presented as mean ± S.E. from the indicated number of experiments. Statistical analysis was performed using SigmaStat 3.5 (Jandel Scientific, San Jose, CA, USA) software. After testing data for normal distribution, the appropriate statistical test has been used; see figure legends. The differences are considered to be significant if Po0.05 indicated by an asterisk, and those at Po0.01 indicated by a double asterisk.
